"JPM is a gigantic event with more than 500 participating companies and several thousand other stakeholders and is one of the most influential events in our industry. For Alzinova, this was a great success, with a large number of high-level meetings scheduled under CDA, where we presented our findings and discussed potential partnerships. We are extremely pleased with the conversations that took place and are very much looking forward to the continued process", says Tord Labuda, CEO of Alzinova AB.

"We are in an extremely exciting phase in the development of ALZ-101 and are of course keen to maximize the development opportunities. Our participation at J.P. Morgan is a very important part, not least when it comes to having the opportunity to sit down with the right representatives of the really big companies. The response was also very positive, and we foresee that the dialogue will continue with the majority of the companies we met in San Francisco, something that we have already had confirmed by several "Big Pharma", says Sebastian Hansson, Business Development Director, Alzinova AB.

About the J.P. Morgan Healthcare Conference
The annual J.P. Morgan Healthcare Conference was held on January 13-16, 2024. The conference is the largest international platform for companies like Alzinova to present their research and development to potential partners and investors. The conference is attended by both large global companies, innovative growing companies and investors with a focus on Life Science. With a focus on Alzinova's innovative vaccine candidate, ALZ-101, which is focused on neutralizing the toxic oligomeric forms of amyloid-beta – a key component in the development of Alzheimer's disease – the company has had the opportunity to deepen contacts and explore strategic collaborations.

For further information, please contact:
Tord Labuda, CEO
E-mail: tord.labuda@alzinova.com

About Alzinova AB
Alzinova AB is a Swedish biopharmaceutical company in clinical development specializing in the treatment of Alzheimer's disease, where the starting point is to attack toxic amyloid-beta oligomers. The lead candidate ALZ-101 is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers that are central to the onset and development of the disease with great accuracy. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases, with around 40 million affected today. Based on the same technology, the company is also developing the antibody ALZ-201, which is currently in preclinical development, and the goal is to further expand the pipeline. The company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com